Please see the Oral Surveillance page (linked below) for more information on: study design, baseline characteristics, coprimary endpoints, and adverse events of special interest, before reading the real-world evidence content. 

Included patients with RA initiating TNFi therapy (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) or XELJANZ with 6-month follow up¹

• 6,241 TNFi initiators (1,889 [30%] monotherapy initiators)¹
• 402 XELJANZ initiators (238 [59%] monotherapy initiators)¹

Efficacy data collected at Month 6¹:

• CDAI score (≤2.8 and >2.8-10)
• mACR20 response^§
• Mean change in CDAI
• Patient-reported pain (VAS)

• Achievement of LDA (CDAI >2.8-10) or remission (CDAI ≤2.8) at Month 6
• mACR20 response^§ rate (no laboratory result) at Month 6

Corrona LLC (the proprietors of the Corrona RA Registry) was rebranded as CorEvitas in March 2021.
The recommended dose of XELJANZ for the treatment of RA in the US is 5 mg BID or 11 mg prolonged-release OD.2
XELJANZ 5mg BID & 11mg prolonged-release QD are the only approved doses for the treatment of RA and PsA in the UK.
§mACR20 response was defined as requiring at least 20% improvement in both tender and swollen joint counts and in two of the following endpoints: Patient’s Global Assessment of disease activity, Physician’s Global Assessment of disease activity, patient-reported pain (VAS), and Health Assessment Questionnaire Disability Index score.
AE=adverse event; CDAI=Clinical Disease Activity Index; CI=confidence interval; LDA=low disease activity; mACR20=modified American College of Rheumatology criteria ≥20% improvement;  RA=rheumatoid arthritis; TNFi = tumour necrosis factor inhibitor; US = United States; MTX = methotrexate; VAS = visual analogue scale 

Additional Prescribing Information:
Enbrel (etanercept): https://www.pfizerpiindex.co.uk/enbrel
Inflectra (infliximab): https://www.pfizerpiindex.co.uk/inflectra

References:
1. Reed GW, et al. Rheumatol Ther. 2019;6(4):573–586.
2. Reed GW, et al. Rheumatol Ther. 2019;6(4)(suppl):573–586.